GLP-1 Drug Decision Quiz

Four questions. Output: the FDA-approved GLP-1 medication (or two) that best matches your profile, with the underlying trial evidence cited at every branch — STEP, SURMOUNT, SELECT, FLOW, STEP-HFpEF, SURMOUNT-OSA, or STEP-TEENS — plus a link to the relevant GLP Watchdog provider ranking.

This decision support is part of GLP Watchdog' living editorial database — 490+ research articles and 710+ clinically-reviewed GLP-1 telehealth providers, sourced only from primary FDA labels and peer-reviewed PubMed literature.

Not medical advice. Decision support for patients is what this offers, built on outcomes-trial evidence and FDA-approved indications. Which medication you actually take is settled with your prescribing clinician, against your full medical history.
1234

Step 1 of 4 — Which BMI range are you in right now?

Not sure of your BMI? Run our BMI calculator first. Foundayo, Saxenda, Zepbound and Wegovy are approved to manage weight long term in adults who have obesity, or overweight plus a weight-related comorbidity. Their trials enrolled at BMI ≥30, or ≥27 with a comorbidity.

Need to calculate? Use the BMI calculator →

How the recommendation logic works

The decision tree is rule-based, not AI-inferred. Every branch traces to either an FDA-approved indication on a specific drug label (Section 1: Indication and Usage) or an outcomes-trial finding from the published clinical literature.

  • BMI eligibility — one threshold appears on the Foundayo, Saxenda, Zepbound and Wegovy labels alike: BMI ≥30, or ≥27 carrying at least one weight-related comorbidity.
  • Type 2 diabetes path — T2D approval covers Rybelsus, Ozempic and Mounjaro. On HbA1c reduction the SURPASS-2 head-to-head puts tirzepatide ahead of semaglutide.
  • Established CV disease — SELECT (Lincoff et al, NEJM 2023, PMID 37952131) showed semaglutide 2.4 mg reduced major adverse cardiovascular events 20% (HR 0.80, 95% CI 0.72-0.90) in 17,604 non-diabetic adults with overweight/obesity and CV disease. Wegovy is preferred for this profile.
  • HFpEF — semaglutide has STEP-HFpEF behind it on exercise capacity and on symptoms.
  • T2D + CKD — FLOW trial (NEJM 2024) showed semaglutide 1 mg reduced the composite kidney outcome 24% (HR 0.76, 95% CI 0.66-0.87) in T2D + CKD. Ozempic is preferred for this profile.
  • Obstructive sleep apnea — in OSA with obesity, SURMOUNT-OSA had tirzepatide taking roughly 50% off the apnea-hypopnea index. No other GLP-1 carries dedicated OSA trial evidence.
  • Adolescent (12-17) — Wegovy is the FDA-approved option, supported by STEP-TEENS (Weghuber et al, NEJM 2022). Tirzepatide and orforglipron are not currently approved in this age range.
  • Stop conditions — a personal or family history of MEN-2 or MTC; breastfeeding; pregnancy, or actively planning one. Treatment in these populations is contraindicated on every FDA GLP-1 label.

References

  1. 1.Novo Nordisk Inc. WEGOVY (semaglutide) injection — US Prescribing Information, Section 1: Indication and Usage. FDA Approved Labeling — DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. 2.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — US Prescribing Information, Section 1: Indication and Usage. FDA Approved Labeling — DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  3. 3.Eli Lilly and Company. MOUNJARO (tirzepatide) injection — US Prescribing Information, Section 1: Indication and Usage (type 2 diabetes). FDA Approved Labeling — DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  4. 4.Novo Nordisk Inc. OZEMPIC (semaglutide) injection — US Prescribing Information, Section 1: Indication and Usage (type 2 diabetes). FDA Approved Labeling — DailyMed (NIH). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  5. 5.Novo Nordisk Inc. RYBELSUS (semaglutide) tablets — US Prescribing Information, Section 1: Indication and Usage (type 2 diabetes). FDA Approved Labeling — DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
  6. 6.Novo Nordisk Inc. SAXENDA (liraglutide) injection — US Prescribing Information, Section 1: Indication and Usage. FDA Approved Labeling — DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
  7. 7.Eli Lilly and Company. FOUNDAYO (orforglipron) tablets — US Prescribing Information, Section 1: Indication and Usage. FDA Approved Labeling — DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
  8. 8.Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023. PMID: 37952131.
  9. 9.Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
  10. 10.Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185.

The branches rest on pivotal trials, among them FLOW, STEP-HFpEF and SURPASS-2.

Data freshnessLast verified Cadence: annual

Source: FDA-approved indications (Section 1 of the Wegovy, Zepbound, Mounjaro, Ozempic, Saxenda, Foundayo and Rybelsus labels) + outcomes-trial evidence (SELECT PMID 37952131, FLOW, STEP-HFpEF, SURMOUNT-OSA, STEP-TEENS, SURPASS-2).

Ready to start? GLP-1 providers we have vetted

Telehealth providers, vetted by us, prescribing GLP-1 online.

Vetted by our editors · no insurance required

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.5

Gala

Moving between compounded and brand without changing seller

7.9

Luvo Health

Moving between compounded and brand without changing seller

6.3

WellMedRx

Comparing compounded and brand GLP-1 plans with a published state list